Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 Jan 18;91(2):822–826. doi: 10.1073/pnas.91.2.822

Genetic heterogeneity of hepatocellular carcinoma.

H Unsal 1, C Yakicier 1, C Marçais 1, M Kew 1, M Volkmann 1, H Zentgraf 1, K J Isselbacher 1, M Ozturk 1
PMCID: PMC43041  PMID: 8290606

Abstract

We studied 80 hepatocellular carcinomas from three continents for p53 gene (TP53) mutations and hepatitis B virus (HBV) sequences. p53 mutations were frequent in tumors from Mozambique but not in tumors from South Africa, China, and Germany. Independent of geographic origin, most tumors were positive for HBV sequences. X gene coding sequences of HBV were detected in 78% of tumors, whereas viral sequences in the surface antigen- and core antigen-encoding regions were present in less than 45% of tumors. These observations indicate that hepatocellular carcinomas are genetically heterogeneous. Mozambican-type of hepatocellular carcinomas are characterized by a high incidence of p53 mutations related to aflatoxins. In other tumors, the rarity of p53 mutations combined with the frequent presence of viral X gene coding sequences suggests a possible interference of HBV with the wild-type p53 function.

Full text

PDF
822

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aden D. P., Fogel A., Plotkin S., Damjanov I., Knowles B. B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979 Dec 6;282(5739):615–616. doi: 10.1038/282615a0. [DOI] [PubMed] [Google Scholar]
  2. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991 Apr 4;350(6317):429–431. doi: 10.1038/350429a0. [DOI] [PubMed] [Google Scholar]
  3. Buetow K. H., Sheffield V. C., Zhu M., Zhou T., Shen F. M., Hino O., Smith M., McMahon B. J., Lanier A. P., London W. T. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9622–9626. doi: 10.1073/pnas.89.20.9622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Challen C., Lunec J., Warren W., Collier J., Bassendine M. F. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology. 1992 Dec;16(6):1362–1366. doi: 10.1002/hep.1840160610. [DOI] [PubMed] [Google Scholar]
  5. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  6. Dusheiko G. M., Brink B. A., Conradie J. D., Marimuthu T., Sher R. Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: a large population survey. Am J Epidemiol. 1989 Jan;129(1):138–145. doi: 10.1093/oxfordjournals.aje.a115102. [DOI] [PubMed] [Google Scholar]
  7. Feitelson M. A., Zhu M., Duan L. X., London W. T. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 1993 May;8(5):1109–1117. [PubMed] [Google Scholar]
  8. Harwood J., Tachibana A., Meuth M. Multiple dispersed spontaneous mutations: a novel pathway of mutation in a malignant human cell line. Mol Cell Biol. 1991 Jun;11(6):3163–3170. doi: 10.1128/mcb.11.6.3163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  10. Hosono S., Chou M. J., Lee C. S., Shih C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene. 1993 Feb;8(2):491–496. [PubMed] [Google Scholar]
  11. Kress S., Jahn U. R., Buchmann A., Bannasch P., Schwarz M. p53 Mutations in human hepatocellular carcinomas from Germany. Cancer Res. 1992 Jun 1;52(11):3220–3223. [PubMed] [Google Scholar]
  12. Lange W., Masihi K. N. Epidemiology and economic importance of hepatitis B in the Federal Republic of Germany. Postgrad Med J. 1987;63 (Suppl 2):21–26. [PMC free article] [PubMed] [Google Scholar]
  13. Li D., Cao Y., He L., Wang N. J., Gu J. R. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis. 1993 Feb;14(2):169–173. doi: 10.1093/carcin/14.2.169. [DOI] [PubMed] [Google Scholar]
  14. Liang T. J., Blum H. E., Wands J. R. Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology. 1990 Aug;12(2):204–212. doi: 10.1002/hep.1840120205. [DOI] [PubMed] [Google Scholar]
  15. Miller J. H. Mutational specificity in bacteria. Annu Rev Genet. 1983;17:215–238. doi: 10.1146/annurev.ge.17.120183.001243. [DOI] [PubMed] [Google Scholar]
  16. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991 Oct 15;51(20):5520–5525. [PubMed] [Google Scholar]
  17. Nishida N., Fukuda Y., Kokuryu H., Toguchida J., Yandell D. W., Ikenega M., Imura H., Ishizaki K. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res. 1993 Jan 15;53(2):368–372. [PubMed] [Google Scholar]
  18. Oda T., Tsuda H., Scarpa A., Sakamoto M., Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 1992 Nov 15;52(22):6358–6364. [PubMed] [Google Scholar]
  19. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 1992 May;15(5):948–963. doi: 10.1002/hep.1840150532. [DOI] [PubMed] [Google Scholar]
  20. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991 Nov 30;338(8779):1356–1359. doi: 10.1016/0140-6736(91)92236-u. [DOI] [PubMed] [Google Scholar]
  21. Parkin D. M., Lärä E., Muir C. S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988 Feb 15;41(2):184–197. doi: 10.1002/ijc.2910410205. [DOI] [PubMed] [Google Scholar]
  22. Paterlini P., Gerken G., Nakajima E., Terre S., D'Errico A., Grigioni W., Nalpas B., Franco D., Wands J., Kew M. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med. 1990 Jul 12;323(2):80–85. doi: 10.1056/NEJM199007123230202. [DOI] [PubMed] [Google Scholar]
  23. Puisieux A., Lim S., Groopman J., Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 1991 Nov 15;51(22):6185–6189. [PubMed] [Google Scholar]
  24. Rideout W. M., 3rd, Coetzee G. A., Olumi A. F., Jones P. A. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990 Sep 14;249(4974):1288–1290. doi: 10.1126/science.1697983. [DOI] [PubMed] [Google Scholar]
  25. Robinson W. S., Klote L., Aoki N. Hepadnaviruses in cirrhotic liver and hepatocellular carcinoma. J Med Virol. 1990 May;31(1):18–32. doi: 10.1002/jmv.1890310106. [DOI] [PubMed] [Google Scholar]
  26. Scheffner M., Münger K., Byrne J. C., Howley P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5523–5527. doi: 10.1073/pnas.88.13.5523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Scorsone K. A., Zhou Y. Z., Butel J. S., Slagle B. L. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res. 1992 Mar 15;52(6):1635–1638. [PubMed] [Google Scholar]
  28. Sell S. The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int J Dev Biol. 1993 Mar;37(1):189–201. [PubMed] [Google Scholar]
  29. Sells M. A., Chen M. L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005–1009. doi: 10.1073/pnas.84.4.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sheu J. C., Huang G. T., Lee P. H., Chung J. C., Chou H. C., Lai M. Y., Wang J. T., Lee H. S., Shih L. N., Yang P. M. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res. 1992 Nov 1;52(21):6098–6100. [PubMed] [Google Scholar]
  31. Takada S., Gotoh Y., Hayashi S., Yoshida M., Koike K. Structural rearrangement of integrated hepatitis B virus DNA as well as cellular flanking DNA is present in chronically infected hepatic tissues. J Virol. 1990 Feb;64(2):822–828. doi: 10.1128/jvi.64.2.822-828.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Van Rensburg S. J., Cook-Mozaffari P., Van Schalkwyk D. J., Van der Watt J. J., Vincent T. J., Purchase I. F. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer. 1985 May;51(5):713–726. doi: 10.1038/bjc.1985.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vogelstein B., Kinzler K. W. The multistep nature of cancer. Trends Genet. 1993 Apr;9(4):138–141. doi: 10.1016/0168-9525(93)90209-z. [DOI] [PubMed] [Google Scholar]
  34. Yen F. S., Shen K. N. Epidemiology and early diagnosis of primary liver cancer in China. Adv Cancer Res. 1986;47:297–329. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES